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ABSTRACT
Introduction: Acute lower respiratory infection (ALRI) is a
leading cause of childhood mortality. Research suggests
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that vitamin D deficiency (VDD) puts children at risk for
ALRI. The purpose of this review is to examine ALRI and
VDD in children 5 years and younger. Common etiologies,
diagnosis, prevention, treatment of ALRI, and recommendations for vitamin D supplementation are summarized.
Method: Databases were searched for studies investigating
VDD and ALRI in children. Independent reviewers assessed
the internal validity of the studies.
Results: Of 18 studies examined, VDD was found to be associated with increased risk or severity of ALRI in 13 studies; associations were not found in 4 studies. In one study it was
found that high maternal vitamin D levels was associated
with ALRI in infants.
Discussion: Vitamin D supplementation is a low-cost, lowrisk intervention that providers should consider for children,
especially those at high risk for ALRI. Practitioners should
follow current recommendations when prescribing vitamin
D supplementation for infants and children. J Pediatr Health
Care. (2014) 28, 572-582.

KEY WORDS
Vitamin D, acute lower respiratory infection, pneumonia,
bronchiolitis

OBJECTIVES
1. Explain the physiology of vitamin D synthesis.
2. Describe the etiology, diagnosis, prevention, and
treatment of acute lower respiratory infections (ALRIs).
3. Discuss the possible associations between vitamin D
deficiency and ALRI.
4. Describe the current recommendations for vitamin D
intake during pregnancy, lactation, and childhood.
5. State the dosing recommendations for the supplementation of vitamin D in children.
6. Describe the adverse effects of vitamin D supplementation and toxicity.
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In 1903 Niels Ryberg Finsen, a Danish doctor,
received the Nobel Prize for discovering a novel and
effective treatment for skin tuberculosis: light. Finsen
cured patients with lupus vulgaris through phototherapy (Nobel Foundation, 1903), and by the 1920s, sun
exposure was an increasingly popular treatment for
tuberculosis (Roelandts, 2002). It was thought that the
efficacy of phototherapy might be due to sunlight
increasing vitamin D levels. After the discovery of antibiotics, light intervention was abandoned. However,
more than a century later, the possibilities of vitamin
D for prevention and treatment of respiratory illnesses
are now being researched again (Camargo et al.,
2011; Manaseki-Holland et al., 2010).
A possible connection between vitamin D deficiency
(VDD) and respiratory infections has been proposed.
As early as 1975, Salimpour (1975) studied 200 rachitic
children (rickets is caused by VDD and calcium deficiency), ages 0 to 14 years, in Tehran, Iran, and found
that 43% also had pneumonia. Research also has associated VDD with acute lower respiratory tract infection
(ALRI), which includes bronchiolitis and pneumonia
(Karatekin, Kaya, Saliho
glu, Balci, & Nuho
glu, 2009;
Roth, Shah, Black, & Baqui, 2010).
The association between ALRI and VDD is important
because ALRI is costly and a leading cause of global
child mortality, annually accounting for approximately
1.4 million deaths of children younger than 5 years
(Black et al., 2010). Globally in 2010, there were an estimated 15 million hospitalizations of children with severe or very severe ALRI (Nair et al., 2013). In the
United States, hospitalization costs for respiratory syncytial virus (RSV) infections, a common cause of bronchiolitis, range from an average of $5069 for children
without underlying comorbidity to an average of
$12,103 for children with chronic lung disease
(Hampp, Kauf, Saidi, & Winterstein, 2011). If vitamin
D could prevent ALRI or decrease the duration and/or
severity of ALRI in children, it could save lives
If vitamin D could
and decrease health
prevent ALRI or
care costs. Therefore,
decrease the
the purposes of this review are threefold: to
duration and/or
describe the etiology,
severity of ALRI in
diagnosis, prevention,
children, it could
and treatment of ALRI;
to conduct a review of
save lives and
literature
regarding
decrease health
the association becare costs.
tween VDD and ALRI
in children 5 years of
age or younger; and to make recommendations for
health care providers regarding vitamin D supplementation to prevent or lessen severity of ALRI in children
5 years of age or younger.
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ETIOLOGY, DIAGNOSIS, PREVENTION, AND
TREATMENT OF ALRI
The term ALRI encompasses both bronchiolitis and
pneumonia. Although both are lower respiratory tract
infections, they are separate diseases with etiological
differences.
Etiology
Bronchiolitis occurs when viruses infect bronchiolar
epithelial cells, causing damage and inflammation in
the bronchioles. RSV is the most common cause of
bronchiolitis, but other causes also exist, including parainfluenza virus, adenovirus, rhinovirus, human metapneumonovirus, coronavirus, and bocavirus (Pavia,
2011). Bronchiolitis is highly contagious and spreads
through direct contact with nasal secretions, airborne
droplets, and fomites, which are contaminated surfaces
that aid the spread of viral infections. RSV bronchiolitis
often leads to a secondary bacterial infection and pneumonia (Thorburn, Harigopal, Reddy, Taylor, & van
Saene, 2006).
Pneumonia is an inflammation of the lung parenchyma, consolidation in the affected area, and filling
of alveolar air spaces with exudate and inflammatory
cells. It may be caused by viruses, bacteria, or a mixed
bacterial and viral infection. The most common viral
and bacterial causes of pneumonia are listed in
Table 1 (Cevey-Macherel et al., 2009). Mycoplasma
pneumoniae and Chlamydia pneumoniae are considered atypical pathogens.
Diagnosis
The diagnosis of bronchiolitis is primarily clinical. The
American Association of Pediatrics (AAP, 2006) defines
bronchiolitis as a set of clinical signs and symptoms,
including initial viral upper respiratory manifestations
followed by increased respiratory effort and wheezing
in children younger than 2 years. Signs of increased respiratory effort include tachypnea, nasal flaring, and
chest retractions. Current evidence does not support
obtaining routine chest radiography for children with
bronchiolitis (AAP, 2006).
Signs and symptoms of pneumonia are similar to
those of bronchiolitis: fever, tachypnea, and respiratory
distress. On examination, decreased lung sounds,
crackles, tactile fremitus, and dullness to percussion
are consistent with pneumonia-induced consolidation.
The presence of an infiltrate on chest radiograph is used
to confirm pneumonia (Barson, 2014).
Prevention and Treatment
Prevention of ALRI is limited primarily to hand
washing and minimizing exposure to bacteria and viruses that cause respiratory infections. Palivizumab
(Synagis) is a vaccine that has been shown to be effective in preventing RSV in infants at high risk for
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TABLE 1. Common etiologies of acute lower
respiratory infection
Disease
Bronchiolitis

Viral pneumonia

Bacterial pneumonia

Pathogen
RSV
Parainfluenza
Adenovirus
Rhinovirus
Human metapneumovirus
Coronavirus
Bocavirus
Influenza
Parainfluenza
Adenovirus
RSV
Human metapneumovirus
Streptococcus pneumoniae
Group A beta-hemolytic streptococcus
Mycoplasma pneumoniae*
Chlamydia pneumoniae*

Note. RSV = respiratory syncytial virus. Data from CeveyMacherel, M., Galetto-Lacour, A., Gervaix, A., Siegrist, C., Bille,
J., Bescher-Ninet, B. . Gehri, M. (2009). Etiology of communityacquired pneumonia in hospitalized children based on WHO clinical guidelines. European Journal of Pediatrics, 168(12), 1429–
1436 and Pavia, A. T. (2011). Viral infections of the lower respiratory tract: Old viruses, new viruses and the role of diagnosis. Clinical Infectious Diseases, 52(Suppl 4), S284–S289.
*Atypical causes.

complications (Winterstein, Hampp, & Saidi, 2012).
According to the most recent policy on palivizumab
of the AAP Committee on Infectious Diseases (2009),
high-risk infants should receive palivizumab once a
month for a maximum of 5 months during RSV season
until they reach 24 months of age, and other premature infants who qualify for prophylaxis should
receive palivizumab monthly for a maximum of
3 months during the RSV season. Palivizumab dosage
is 15 mg per kg (AAP Committee on Infectious
Diseases, 2009) and costs on average $1074 per 50mg vial (Mahadevia, Masaquel, Polak, & Weiner,
2012), making the treatment cost for a 3-kg infant
approximately $966 for a single dose of palivizumab,
or approximately $5000 for 5 months’ administration
early in life. As the child grows, so does the dose
required. In the second year of life, the cost can be
$3000 per month (for a child who weighs more than
10 kg) or up to $15,000 for 5 months of the RSV season
(Hampp et al., 2011). In Florida’s Medicaid population,
Hampp and associates (2011) concluded that the cost
of palivizumab prophylaxis to prevent RSV-related
hospitalizations ‘‘far exceeded the savings associated
with prevented hospitalizations’’ (p. 502). This costbenefit analysis highlights the need to identify less
costly ways to prevent and treat RSV-related ALRIs.
Current treatment of ALRI is mostly supportive. Nasopharyngeal suctioning, oxygen therapy, intravenous
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fluids, and antipyretic agents might be used. Antibiotics
and antiviral drugs are sometimes administered
whether the infection is thought to be bacterial or viral
(Kabra, Lodha, & Pandey, 2010).

VITAMIN D AND VITAMIN D DEFICIENCY
Vitamin D, an essential steroid hormone, is primarily
synthesized in the skin and liver from sun exposure,
but it can also be obtained through dietary intake or
supplements (Holick, 2007). Both lower and upper
limits of healthy serum vitamin D levels are unclear.
The Institute of Medicine (IOM, 2011) defines VDD as
a serum level less than 20 ng/ml, but in research studies
the threshold for VDD varies widely (Holick, 2007). Researchers have questioned whether current recommendations of vitamin D intake are sufficient for optimal
health outcomes (Bischoff-Ferrari, Giocannucci,
Willett, Dietrich, & Dawson-Hughes, 2006; Mansbach,
Ginde, & Camargo, 2009).
Although vitamin D is fairly simple to obtain, an estimated 1 billion people worldwide have vitamin D insufficiency (21-29 ng/ml) or deficiency (Holick, 2007).
Cultural and health practices can contribute to vitamin
D insufficiency or VDD by preventing infants from
acquiring vitamin D from sun exposure. First, in some
cultures infants are swaddled when outdoors, minimizing their sun exposure (Najada, Habashneh, &
Khader, 2004). Second, applying sunscreen to limit
the sun’s damage to skin is recommended, especially
in children, because 25% of lifetime sun exposure is
estimated to occur before 18 years of age, a time of
high vulnerability to the potentially toxic effects of
sun exposure (Balk & AAP, Council on Environmental
Health and Section on Dermatology, 2011). However,
sunscreen suppresses cutaneous synthesis of vitamin
D3 by blocking the absorption of ultraviolet B radiation
(Matsuoka, Ide, Wortsman, MacLaughlin, & Holick,
1987). Third, mothers are likely to have vitamin D insufficiency or VDD for the same reasons as their infants
(Lee et al., 2007). At its best, breast milk provides little
vitamin D and even less if a mother is vitamin D deficient (Wagner & Greer, 2008).
Because vitamin D is primarily synthesized through
sun exposure, VDD appears to follow a seasonal
pattern of higher vitamin D levels during summer and
lower levels in winter (Shoben et al., 2011). Interestingly, researchers have found associations between
VDD and seasonal respiratory illnesses, such as upper
respiratory infections (Ginde, Mansbach, & Camargo,
2009). Grant (2008) hypothesized that sun exposure
and its effect on vitamin D levels could help explain
the seasonality of childhood respiratory infections,
such as bronchiolitis or pneumonia, which peak in
the winter when sunlight is scarce and dissipate in the
summer.

Journal of Pediatric Health Care

METHODS
Identification of Studies
An electronic search was conducted to identify studies
from 2004-2014 in the following databases: Medline, CINAHL, and the Cochrane Library. Search terms used
were vitamin D, 25-hydroxyvitamin D, child, maternal,
infant, respiratory, infection, and pneumonia. References from relevant articles were reviewed for applicable studies. We included one classical study
published prior to 2004 (Muhe & Lulseged, 1997).
Only English articles evaluating the relationship between vitamin D and ALRI in children 0 to 5 years of
age were included. Studies were excluded if they
included adults or children older than 5 years of age
or focused on asthma. A total of 18 articles met the
criteria for the review, including 6 cohort studies, 8
case-control studies, 1 retrospective case study, 1
cross-sectional study, and 2 randomized controlled
trials.
Conversion of Measurement and VDD
Definitions
The thresholds for determining VDD vary widely, from
9 to 20 ng/ml. This variation makes it difficult to
compare findings of the studies. Further adding to comparison challenges, two different units of measurement
were used in the reviewed studies to assess vitamin D
levels: nanomole per liter and nanogram per milliliter.
We converted all values to nanograms per milliliter to
facilitate comparison between studies. For converting
vitamin D levels, 1 nmol/L equals 0.4 ng/ml (National
Institutes of Health, 2011). Therefore, values in nanomoles per liter were multiplied by 0.4 to convert to
nanograms per milliliter.
Assessment of Internal Validity
The two authors independently assessed the studies’ internal validity using the United States Preventive Services Task Force (USPSTF) criteria (Harris et al., 2001).
Each study is given a rating of good, fair, or poor based
on the criteria for the specific type of study (Table 2). A
good study meets all criteria listed, a fair study fails to
meet all criteria but does not have a fatal flaw, and a
poor study contains a fatal flaw.
Review of Literature
Internal validity of the studies was assessed. Major
topics of the reviewed studies included rickets and
ALRI, the correlation between VDD and ALRI, the
severity of ALRI, and the effect of vitamin D on the immune system.
Internal Validity of Studies
Using the USPSTF criteria, the authors rated the internal
validity of each of studies included in the literature review as fair. Weaknesses that prevented the studies
from obtaining a ‘‘good’’ rating included high loss to
www.jpedhc.org

follow-up, failure to consider all important outcomes,
or failure to adjust for potential confounding variables.
According to the authors’ assessment, none of the
studies had a fatal flaw, which is required for a ‘‘poor’’
rating.
RESULTS
Rickets and ALRI
Two research groups found significant associations between rickets, which is caused by VDD and calcium
deficiency, and ALRI. In both studies, rickets was identified by clinical signs and confirmed by wrist radiograph. First, in a matched case-control study in the
Ethio-Swedish Children’s Hospital in Ethiopia, rickets
was significantly more prevalent among the 500 children younger than 5 years of age admitted with pneumonia than it was among the 500 control subjects
with no evidence of pneumonia (210 vs. 20, matched
odds ratio 22.11, p < .0001; Muhe & Lulseged, 1997).
However, these researchers did not find an increase in
mortality of children with pneumonia and rickets
compared with children who only had pneumonia
(relative risk [RR] 1.16, p = .20). Second and similarly,
Najada and colleagues (2004) conducted a study
involving 443 infants aged 0 to 24 months in Amman,
Jordan, and found that significantly more rachitic infants were admitted with lower respiratory tract diseases than were nonrachitic control subjects (85% vs.
30%, p < .01). The length of hospital stay was significantly longer for rachitic infants than for nonrachitic infants (9.5 days vs. 7.4, p = .002).
In the study by Muhe and Lulseged (1997), the case
and control groups differed significantly in family
size, birth order, number of people living in their
homes, and months of exclusive breastfeeding. However, even after controlling for these variables, the incidence of rickets among children with pneumonia was
still 13 times higher than among control subjects
(13.37, p < .001). The rachitic and nonrachitic children
in the study by Najada and colleagues (2004) also
differed significantly in the birth order of the child, family size, mode of feeding, outdoor dressing of mothers
(covering the body with thick, dark clothing), and the
presence of anemia; however, Najada and colleagues
did not state whether they controlled for these variables
in their analysis.
Correlation Between Vitamin D Level and ALRI
Research has also been conducted regarding the correlation between infant vitamin D levels and ALRI. In two
studies it was found that 25(OH)D levels were significantly lower in infants with ALRI than in control subjects
(Karatekin et al., 2009; Roth et al., 2010). Karatekin and
colleagues (2009) studied 25 newborns with ALRI and
15 healthy newborn control subjects in Istanbul,
Turkey, and found that newborns (within the first
28 days of life) with ALRI had significantly lower serum
November/December 2014
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TABLE 2. U.S. Preventive Services Task Force criteria for grading internal validity
Study design
Systematic review

Case-control studies

RCTs and cohort studies

Diagnostic accuracy studies

Criteria
Comprehensiveness of sources/search strategy used
Standard appraisal of included studies
Validity of conclusions
Recency and relevance
Accurate ascertainment of cases
Nonbiased selection of cases/control subjects with exclusion criteria applied equally to both
Response rate
Diagnostic testing procedures applied equally to each group
Appropriate attention to potential confounding variables
Initial assembly of comparable groups
For RCTs: adequate randomization, including concealment and whether potential confounders
were distributed equally among groups
For cohort studies: consideration of potential confounders with either restriction or measurement for
adjustment in the analysis; consideration of inception cohorts
Maintenance of comparable groups (includes attrition, crossovers, adherence, contamination)
Important differential loss to follow-up or overall high loss to follow-up
Measurements: equal, reliable and valid (includes masking of outcome assessment)
Clear definition of interventions
All important outcomes considered
Analysis: adjustment for potential confounders for cohort studies, or intention to treat analysis for RCTs
Screening test relevant, available for primary care, adequately described
Study uses a credible reference standard, performed regardless of test results
Reference standard interpreted independently of screening test
Handles indeterminate results in a reasonable manner
Spectrum of patients included in study
Sample size
Administration of reliable screening test

Note. RCT = randomized controlled trial. From Harris, R. P., Helfrand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D.
(2001). Current methods of the U.S. Preventive Services Task Force. American Journal of Preventive Medicine, 20(3S), 21–35.
Reprinted with permission.

25(OH)D concentrations than did control newborns
(9.12  8.88 ng/ml vs. 16.33  13.42 ng/ml, p = .011).
Roth and colleagues (2010) had similar results when
comparing 25 case-control pairs in Sylhet, Bangladesh.
The cases, children 1 to 18 months of age who were
hospitalized with ALRI, were matched to control subjects based on age, sex, and village. In their study, the
mean serum 25(OH)D of the cases was significantly
lower than that of the control subjects (11.6 vs.
15.6 ng/ml, p = .015).
In three studies an association also was found between infant ALRI and cord blood or maternal vitamin
D levels. In a prospective birth cohort study of 156 infants in the Netherlands, Belderbos and colleagues
(2011) found that low levels of vitamin D in the cord
blood increased the risk of RSV within the first year of
life. Infants with a 25(OH)D cord blood level < 20 ng/
ml had an adjusted relative risk of 6.2 compared with
infants who had a 25(OH)D cord blood level
$ 30 ng/ml (95% confidence interval [CI], 1.6-24.9;
p = .01). Camargo and colleagues (2011) conducted a
similar study in New Zealand and found that in newborns with 25(OH)D cord blood levels < 10 ng/ml, respiratory infections were twice as likely to develop by
3 months of age compared with 3-month-old infants
who had 25(OH)D cord blood levels $ 30 ng/ml
576
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(adjusted odds ratio [OR], 2.04) as newborns. Likewise,
Morales and colleagues (2012) studied 1693 children
younger than 5 years of age in Spain and found that
higher maternal vitamin D levels during pregnancy
were associated with a decreased risk of ALRI in the infants’ first year of life (Quartile 4 vs. Quartile 1: OR, 0.67;
95% CI, 0.50-0.90; p = .016).
Not all researchers found a decrease in ALRI with
increased vitamin D levels. Roth, Jones, Prosser,
Robinson, and Vohra (2009) conducted a study in Alberta, Canada, and did not find a significant difference
in VDD between 64 cases of ALRI and 65 control subjects without a history of hospitalization for ALRI, using
either the 25(OH)D threshold of < 16 ng/ml (4.7 vs.
1.5%, p = .365) or < 32 ng/ml (51.6 vs. 56.9%,
p = .598). McNally and colleagues (2009) similarly
found no difference in mean vitamin D levels between
105 children with ALRI and 92 control children in Saskatchewan, Canada (32.4  15.6 vs. 33.2  12.0 ng/
ml, p = .71). However, the difference in prevalence of
25(OH)D levels < 20 ng/mL between the pneumonia
subgroup and control subjects was approaching significance (30% vs. 16%, p = .07). In a secondary analysis of
the same data, Leis and colleagues (2012) found that
children with a vitamin D intake of less than 80 IU/
kg/day were more than four times more likely to have
Journal of Pediatric Health Care

ALRI compared with children who had a vitamin D
intake exceeding 80 IU/kg/day (OR, 4.9; CI, 1.5-16.4).
Also while studying dietary intake of vitamin D,
Camargo and colleagues (2007) conducted research
on 1194 mother-child pairs in Massachusetts and did
not find an association between mothers’ intake of
vitamin D and their infants’ risk of respiratory infection
(p = .09). The children were enrolled in the study at
birth, and respiratory infection status was evaluated at
6 months, 12 months, and 24 months.
Severity of ALRI
Some researchers investigated the role of vitamin D in
the severity of ALRI in children. In a case-control study
in India, Wayse, Yousafzai, Mogale, and Filteau (2004)
found that serum 25(OH)D levels > 9 ng/ml was associated with a significantly lower risk of severe ALRI (OR,
0.09; 95% CI, 0.03-0.24; p < .001). In a study of 152 children younger than 59 months of age with pneumonia at
Al-Sabeen hospital in Sana’a, Yemen, VDD was an independent predictor of persistent hypoxemia for children
admitted with pneumonia (p = .021; Banajeh, 2009).
Rachitic children were four times more likely than nonrachitic children to fail to respond to treatment 30 days
after enrollment in the study (20.6 vs. 6%; 95% CI,
1.2-14.4; p = .029). Treatment failure was defined as
modification of treatment because of worsening clinical
condition, development of a comorbid condition, such
as bacterial meningitis, or death. Likewise, Inamo and
colleagues (2011) studied 28 infants in Tokyo, Japan,
and found that, compared with infants who had
25(OH)D levels of 6 ng/ml or more, infants with
25(OH)D levels of < 4 ng/ml were significantly more
likely to need supplementary oxygen and ventilator
management (p < .01). Similarly, McNally and
colleagues (2009), previously discussed, found that
children with ALRI in a Canadian pediatric intensive
care unit had significantly lower vitamin D levels than
did control subjects, who were children hospitalized
for something other than ALRI (19.6  9.6 vs.
33.2  12.0 ng/ml, p = .001). These studies suggest
that VDD might increase the severity of a respiratory
infection and that infants and children with VDD and
ALRI might require higher levels of care than children
with sufficient vitamin D levels.
Other researchers did not find a difference in severity
of ALRI and vitamin D. In a double-blind randomized
controlled trial in inner-city Kabul, Afghanistan, baseline vitamin D levels were not measured, but researchers compared oral vitamin D supplementation
with placebo in 224 children with pneumonia. They
found no difference in mean days to recovery between
the group who received vitamin D supplements and the
group who received placebos (4.74 vs. 4.98 days,
p = .17; Manaseki-Holland et al., 2010). Additionally,
Carroll and colleagues (2011) did a cross-sectional
study of 252 mother-infant dyads in Tennessee and
www.jpedhc.org

compared the mothers’ vitamin D level with their infants’ bronchiolitis score, which is a tool used to assess
severity of respiratory symptoms. In propensity scoreadjusted sensitivity models, Carroll and colleagues did
not find a significant association between the maternal
25(OH)D level and the infants’ bronchiolitis score
(adjusted OR, 0.76; 95% CI, 0.52-1.11). Infant vitamin
D levels were not measured in the study.
In contrast, Gale and colleagues (2008) found an association between high prenatal 25(OH)D levels and
subsequent increased incidence of ALRI in the mothers’
infants. In their study, conducted in Southampton,
United Kingdom, they compared mothers in late pregnancy who were in the lowest quarter of 25(OH)D
levels with counterparts in the highest quarter of
25(OH)D levels and found that mothers in the highest
quarter were significantly more likely to report a diagnosis of pneumonia or bronchiolitis in their infants
(OR, 4.80; 95% CI, 1.01-22.73). Infants’ 25(OH)D levels
were not evaluated. The study by Gale and colleagues
(2008) was the only study located that found an association between high prenatal vitamin D level and an
increased risk of ALRI in infants.
Effects on Immune System
Two research groups investigated the effect of vitamin D
on the immune system during ALRI. In a study in Sana’a,
Yemen, Banajeh (2009) found that VDD significantly
decreased the percentage of circulating polymorph nuclear neutrophils (37% vs. 47%; adjusted OR, 0.71; 95%
CI, 0.53-0.95; p = .02), which are important innate immune cells that migrate into the lung tissues and kill bacteria and viruses through phagocytosis. In a randomized
controlled trial conducted in Afghanistan by ManasekiHolland and colleagues (2010), 224 children admitted
with pneumonia were randomly assigned to receive
either a single-dose 100,000 IU oral vitamin D supplement or a placebo. No vitamin D levels were assessed
during the trial, and it was not stated when the supplements or placebos were administered. ManasekiHolland and associates (2010) assessed the frequency
of repeat pneumonia episodes during the 90-day posttreatment period. Children who received a vitamin D
supplement had a significantly lower risk of a repeat
episode compared with children who received a placebo (92 vs. 122; RR, 0.78; 95% CI, 0.64-.94; p=.01).
These results suggest vitamin D supplementation might
strengthen the immune system. Because ManasekiHolland and colleagues (2010) did not assess vitamin
D levels, it is not known whether the children had VDD.
In the double-blind randomized controlled trial
by Manaseki-Holland and associates (2012) in
Afghanistan, 3046 infants aged 1 to 11 months were
randomly assigned to oral administration of either
vitamin D3, 100,000 IU, or a placebo every 3 months
for 18 months. These investigators did not find a significant difference in incidence of pneumonia between
November/December 2014
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the placebo group (0.137 per child per year; 95% CI,
0.121-0.155) and the vitamin D group (0.145 per child
per year; 95% CI, 0.129-0.164).
During three previously discussed studies
(Manaseki-Holland et al., 2010; Manaseki-Holland
et al., 2012; and Najada et al., 2004), vitamin D supplements were administered. Supplements given were
100,000 IU orally once (Manaseki-Holland et al.,
2010), 100,000 IU orally every 3 months for 18 months
(Manaseki-Holland et al., 2012), and 600,000 IU via
intramuscular injection once (Najada et al., 2004). Parents did not report any adverse reactions to or adverse
effects from vitamin D supplements administered to
their children.
DISCUSSION
Limitations of Studies
All studies have limitations, and the studies reviewed
were no exception. The limitations included lack of a
consistent unit of measurement and thresholds, weaknesses in research methods, inconsistencies in control
groups, not reporting the season of the study, and viral
versus bacterial cause.
Lack of consistent unit of measurement and
thresholds
Comparing results from the studies was difficult
because they varied in unit of measurement and definition of VDD. Some studies did not define VDD. When
VDD was defined, either nanogram per milliliter or
nanomole per liter was the unit of measurement. As
needed, we converted vitamin D values to nanogram

per milliliter to facilitate comparison between studies.
In addition, researchers used thresholds ranging from
9 to 20 ng/ml to determine VDD (see Table 3). This
range could explain why some studies found that
VDD was significantly associated with ALRI in children,
but others did not. When using a higher threshold, researchers would be less likely to detect a difference in
prevalence of VDD between cases with ALRI and control subjects.
Weaknesses in Research methods
Different results might also be explained by lack of rigor
in assessment tools. Gale and colleagues (2008) and
Camargo and associates (2007) used maternal recall to
determine if the mother’s infant had ever been diagnosed with respiratory infections such as pneumonia,
bronchiolitis, croup, or bronchitis. Camargo and
colleagues (2007) further relied on maternal recall by
asking mothers to complete a food frequency questionnaire and then using the information to assess vitamin D
intake. Maternal self-report can be inaccurate because
mothers might incorrectly remember past events or
not understand the questions. Also, mothers might hesitate to report their children’s illnesses if they believe reporting illnesses would reflect poorly on their abilities
as mothers and be less socially acceptable (Lau, Hurst,
Smith, & Schanler, 2007).
Bronchiolitis scores were used exclusively to assess
illness severity in the study by Carroll and colleagues
(2011), and individual scores were based on respiratory
symptoms at one point in time. Trends in bronchiolitis
scores are helpful in determining illness trajectory and

TABLE 3. Definitions of vitamin D sufficiency, insufficiency, and deficiency by 25(OH)D level in
nanograms per milliliter
Author

Definition of VDS

Banajeh (2009)
Belderbos et al. (2011) No explicit definitions but four comparison
groups used: < 10, < 20, 20-29.6, and $ 30
Camargo et al. (2011) No explicit definitions but categorized into
three groups: < 9.9, 10-29.9, and $ 30
Carroll et al. (2011)
> 12
Gale et al. (2008)
No explicit definitions but four groups
compared: < 12, 12-20, 20-30, > 30
Inamo et al. (2011)

Definition of VDI

< 12

8-12

<8

# 15
Severe VDD: # 5
Two cut-offs used: < 10 (suggested by testing
kit manufacturer) and < 20 (consensus of
scientific understanding)

Karatekin et al. (2009)

Leis et al. (2012)
Manaseki-Holland
et al. (2010)
McNally et al. (2009)
Morales et al. (2012)
Roth et al. (2009)
Wayse et al. (2004)

Definition of VDD

30-32
< 20 considered ‘‘suboptimal’’

< 12 associated with rickets
< 30
< 30
< 16

< 20
< 10
<9

Note. VDD = vitamin D deficiency; VDI = vitamin D insufficiency; VDS = vitamin D sufficiency. 25-hydroxyvitamin D (25[OH]D) is a biomarker of
vitamin D status in circulation (Roth et al., 2010, p. 289).
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effectiveness of respiratory treatments. However, the
researchers used a single bronchiolitis score for each
child, which does not accurately reflect the extent or
severity of illness over time. Additionally, Carroll and
colleagues did not specify when the bronchiolitis score
was determined, and scores can vary widely, depending on the timing of assessment (e.g., on admission
versus prior to discharge) and when the infant had
last undergone suctioning or received a respiratory
treatment. These data collection methods have weaknesses that could affect the study’s results.
Another weakness is the lack of data on serum
vitamin D levels. Neither randomized controlled trial
(Manaseki-Holland et al., 2010; Manaseki-Holland
et al., 2012) measured serum vitamin D levels either
prior to administering vitamin D supplementation or
after administration. Without these data, the
participants’ initial vitamin D status and the impact of
supplementation are unknown.
Control group
Researchers of the case-control studies differed on the
criteria used for control participants. Some researchers
recruited control subjects who were healthy children
with no history of ALRI coming to a clinic for immunizations (Karatekin et al., 2009) or receiving elective surgery
at the hospital (Roth et al., 2009). Roth and colleagues
(2010) used population-based sampling to find control
subjects with no history of ALRI from the same villages
as the cases in their study. In contrast, other researchers
used control subjects who were children admitted to the
hospital for illnesses other than ALRI (McNally et al.,
2009; Muhe & Lulseged, 1997). Because of the effect
that vitamin D has on the immune system, children in
this control group could have had low vitamin D
levels as well. The various sampling methods used to
determine control groups make it challenging to
compare studies and generalize the results.
Season of study
The season during data collection might also limit
generalizability of the studies. Belderbos and
colleagues (2011) found that 25(OH)D concentrations
had a seasonal distribution, with the maximum point
in July and the lowest point in January. They found a
positive correlation between cord blood 25(OH)D level
and monthly sun hours according to data from the
Royal Netherlands Meteorological Institute (r = 0.196,
p = .01). Differing seasons could also explain differences in the researchers’ findings. For example, four
studies were conducted during winter months
(Carroll et al., 2011; Karatekin et al., 2009; Roth et al.,
2009; Roth et al., 2010). During the winter,
participants’ vitamin D levels were likely affected by
the lack of sunlight. This situation could be a
confounding factor that did not seem to be
considered in some studies.
www.jpedhc.org

Bacterial versus viral cause
Another factor potentially affecting the results of the
studies is whether the ALRI was caused by a bacteria
or virus. Roth and colleagues (2009) found no difference between cases and control subjects in prevalence
of vitamin D insufficiency in Canada. In contrast, Wayse
and colleagues (2004) found adequate serum vitamin D
to be associated with a lower risk of ALRI in India. Roth
and colleagues (2009) suggested that the causative
agent might explain the difference in findings between
their study and the study by Wayse and associates
(2004), noting that bacterial pneumonia is common in
developing countries like India, but the study by Roth
and associates (2009) in Canada included mostly patients with viral ALRI. Vitamin D might have a different
effect on bacterial versus viral ALRI.
Treatment of Vitamin D Deficiency
Maternal and Child vitamin D
Because research indicates a possible association between low vitamin D and ALRI in children younger
than 5 years old, maintaining both maternal vitamin D
levels during pregnancy and the infants’ own vitamin
D levels might be protective against ALRI. The IOM
and AAP have made recommendations regarding
vitamin D intake. For pregnant and lactating women,
a daily intake of 600 IU vitamin D per day is recommended (IOM, 2011). Most prenatal vitamins contain 400 IU
vitamin D. For all
breastfed infants, the
.health care
AAP recommends a
providers should
400 IU vitamin D supdiscuss vitamin D
plement daily beginning soon after birth
intake during wellfor all breastfed infants,
child visits and
as well as children who
encourage suppleconsume less than 1 L
of vitamin D–fortified
mentation,
formula or milk per
especially for
day and adolescents
pregnant women
who obtain less than
400 IU vitamin D per
and children, and in
day through vitamin
accordance with
D–fortified milk or
current guidelines.
foods
(Wagner
&
Greer, 2008). Vitamin
D supplementation forms for infants and children are
listed in Table 4 (Casey et al., 2010). Of note, there is
a discrepancy between the multivitamin dose manufacturers recommend for 2- and 3-year-old children (1/2
tablet, 200 IU) and the amount of vitamin D the AAP recommends for vitamin D supplementation (400 IU).
Although further research is needed, health care providers should discuss vitamin D intake during wellchild visits and encourage supplementation, especially
for pregnant women and children, and in accordance
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TABLE 4. Vitamin D supplementation forms for infants and children
Population
Breastfed infants and children younger
than 2 years

Children who consume less than 1 L
vitamin D–fortified milk per day and
adolescents who do not obtain 400 IU
vitamin D per day through vitamin
D-fortified milk and foods

Brand

Recommended daily dose and vitamin
D concentration

Enfamil Poly-Vi-Sol

1 ml contains 400 IU

Carlson Baby D
Just D
Twinlab Infant Care Multivitamin Drop
Centrum Kids Complete Multivitamin,
chewable

1 drop contains 400 IU
1 ml contains 400 IU
1 ml contains 400 IU
One tablet for children 4 years and older,
contains 400 IU; ½ tablet for children 2
and 3 years of age

Flintstone Children’s Complete
Multivitamin, chewable

One tablet for children 4 years and older,
contains 400 IU; ½ tablet for children 2
and 3 years of age
Two gummies for children 4 years and
older, each gummy contains 200 IU; one
gummy for children 2 and 3 years of age
Two gummies for children 2 years and
older; each gummy contains 200 IU

Flintstone Gummies with Calcium
and Vitamin D, multivitamin
Disney Gummies Children’s Multivitamin

Data used with permission from Casey, C. F., Slawson, D. C., & Neal, L. R. (2010). Vitamin D supplementation in infants, children, and
adolescents. American Family Physician, 81(6), 745–748.

with current guidelines. Most infants are not consuming
adequate vitamin D according to the 2008 AAP guidelines. A study in 2010 found that only 5% to 13% of
breastfed infants are receiving the recommended oral
vitamin D supplements (Perrine, Sharma, Jefferds,
Serdula, & Scanlon, 2010). Health care providers should
also consider assessing vitamin D levels for children
who have a risk factor for vitamin D deficiency, such
as poor dietary vitamin D intake and/or limited sunlight
exposure (Mithal et al., 2009), or for women who are
pregnant or lactating (Holick, et al., 2011).
Cost
Health care providers should consider the cost of
vitamin D supplementation. It is a relatively inexpensive and could be used in addition to palivizumab for
high-risk infants and independently for infants and children in general. Additionally, if vitamin D supplements
help prevent ALRI or decrease severity, it saves expenses associated with treatment or hospitalization.
Adverse effects
Health care providers should also be aware of adverse
effects when supplementing with vitamin D. The three
research groups that provided vitamin D supplementation reported no adverse events in their studies
(Manaseki-Holland et al., 2010; Manaseki-Holland
et al., 2012; Najada et al., 2004). Vitamin D is generally
well tolerated, but toxicity causes hypercalcemia. The
symptoms of hypercalcemia include constipation,
anorexia, nausea, and vomiting initially, and then
polyuria, nocturia, and polydipsia after renal
impairment (Lewis, 2009). Symptoms of hypercalcemia
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can be avoided if 25(OH)D levels are monitored and
vitamin D dosage is adjusted accordingly. Health care
providers should aware of these potential toxicity
symptoms and watch for them in their patients.
Adequacy of current supplements
For pregnant or lactating women, the IOM (2011) established 600 IU of vitamin D per day as adequate.
Currently, most prenatal vitamins only contain 400 IU
of vitamin D, so this might not be enough vitamin D
in prenatal vitamins. In one study of healthy women,
the majority were taking a daily prenatal vitamin, but
50% of the women and 65% of their newborns were
vitamin D deficient (25[OH]D < 12 ng/ml) at birth (Lee
et al., 2007). In addition, in a study of high-dose vitamin
D supplements in lactating women, Hollis and Wagner
(2004) found a maternal intake of 4000 IU/day was
required to provide adequate vitamin D for both
mothers and their breastfed infants, approximately 6.5
times the IOM’s recommendation. These findings suggest an implication for policy, which would be to increase the recommended amount of vitamin D in
prenatal vitamins.
Vitamin D Fortification
Another implication of these findings is the need for
vitamin D–fortified food in developing countries. The
prevalence of rickets in some of the studies indicates
the severe need for vitamin D. Natural food sources of
vitamin D—mushrooms, alfalfa, and fatty fish—are
not typically included in the infant diet. However, fortifying foods commonly eaten by infants could prevent
both rickets and ALRI.
Journal of Pediatric Health Care

IMPLICATIONS FOR RESEARCH
Further research is needed. Most of the studies on ALRI
and vitamin D levels have been case-control or birth
cohort studies. It appears that giving vitamin D to
mothers and infants might be beneficial, but only two
randomized controlled trials have been performed to
investigate vitamin D supplementation as an intervention (Manaseki-Holland et al., 2010; ManasekiHolland et al., 2012). Future randomized controlled
trials should investigate the use of a daily vitamin D
supplement, involve healthy infants or pregnant
women as subjects, and follow up longitudinally.
Additionally, randomized controlled trials should
specify when the supplementation is given and report
any adverse effects of vitamin D supplementation.
CONCLUSION
VDD was prevalent among both mothers and infants in
multiple studies. In several of the studies it was found
that VDD was associated with increased risk for ALRI
(Banajeh, 2009; Belderbos et al., 2011; Camargo et al.,
2011; Inamo et al., 2011; Karatekin et al., 2009;
Manaseki-Holland et al., 2010; McNally et al., 2009;
Morales et al., 2012; Muhe and Lulseged, 1997; Najada
et al., 2004; Roth et al., 2010; Wayse et al. 2004);
however, a few did not find an association between
VDD and ALRI (Camargo et al., 2007; Carroll et al.,
2011; Gale et al., 2008; Manaseki-Holland et al., 2012;
Roth et al., 2009). More research is needed to
determine the role that vitamin D plays in the
prevention and treatment of ALRI and the impact
supplementation can have. However, vitamin D
supplementation is a low-cost, low-risk intervention
that providers should consider for children, especially
those at high risk for ALRI.
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